Delve Bio, Inc
Advertisement
Delve Bio, Inc., based in Boston, MA, specializes in advanced genomic diagnostics for central nervous system infections through its innovative product, DelveDetect. This metagenomic sequencing test identifies various pathogens—including bacteria, viruses, fungi, and parasites—using just 1 mL of cerebrospinal fluid, delivering results in 48 hours with a 22% greater diagnostic yield compared to traditional methods.
As an exclusive licensee of the University of California, San Francisco's metagenomic technology, Delve Bio aims to transform the diagnosis of meningitis and encephalitis by providing comprehensive pathogen identification from a curated database of over 68,000 unique species. Supported by extensive real-world evidence from thousands of patient samples, DelveDetect represents a significant advancement in infectious disease testing.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Advertisement
